Quality Scores
AI Summary
Sellas Life Sciences (SLS) is a late-stage clinical biopharmaceutical company primarily focused on the development of novel cancer immunotherapies, specifically its lead candidate Galinpepimut-S (GPS). The company has faced a decade-long struggle with continuous net losses, zero product revenue, and frequent capital raises that have severely diluted long-term shareholders. Its financial history is characterized by a reverse merger and multiple pivots to sustain operations. While the company pursues orphan drug designations and Phase 3 trials, it operates in a high-risk environment with a…
Top Opportunities
- GPS (Galinpepimut-S) targeting Wilms Tumor 1
- Advanced Phase 3 REGAL trial in AML CR2
- Fast Track and Orphan Drug designations
Top Risks
- No product revenue recorded to date
- Persistent and accelerating net losses
- Continuous equity dilution hurting long-term holders
Latest report: Read the annual report summary →
Earnings update: Read the AI earnings call summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.